Showing 1 - 10 of 17,523
prevention of vertebral fractures in postmenopausal women with osteoporosis. Design: A retrospective, incremental cost … formed the efficient frontier in the following order: 1. calcium -> no therapy; 2. ovarian hormone therapy (OHT) -> calcium … -> no therapy [166 Canadian dollars ($Can)]; 3. OHT -> etidronate -> calcium -> no therapy ($Can2331); and 4. OHT …
Persistent link: https://www.econbiz.de/10005449086
Osteoporosis constitutes a major public health problem through its association with fractures at several skeletal sites …-effective use of these pharmacological agents has become a focus for health economic research in osteoporosis. Such research will …
Persistent link: https://www.econbiz.de/10005243023
Specific regulatory guidelines dictate that developing a new drug for osteoporosis will be significantly more expensive … $US86 million for non-estrogen osteoporosis compounds following a minimum programme designed to gain indications for both … investment on an osteoporosis drug will be a minimum of $US95 million greater per launched compound. Many ongoing osteoporosis …
Persistent link: https://www.econbiz.de/10005590530
Denosumab in Osteoporosis every 6 Months) trial. It is becoming increasingly important to evaluate not only the therapeutic …). Analyses were performed in populations (aged ≥60 years) in which osteoporosis medications are currently reimbursed in many … appears to have the potential to become a first-line treatment for post-menopausal women with osteoporosis. However, further …
Persistent link: https://www.econbiz.de/10011005074
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of denosumab (Amgen Inc., UK) to submit evidence for the clinical and cost effectiveness of denosumab for the prevention of fragility fractures in post-menopausal women, as part of the Institute's single...
Persistent link: https://www.econbiz.de/10010614383
Postmenopausal osteoporosis is characterized by an increased rate of bone turnover accompanied by a reduction in bone …, osteoporosis. Alendronate produces sustained increases in BMD and reductions in bone turnover from baseline, and reduces the risk … of vertebral, hip, wrist, and other fractures in women with postmenopausal osteoporosis. It also prevents bone loss, and …
Persistent link: https://www.econbiz.de/10005404679
Background: The German osteology umbrella organization, Dachverband Osteologie (DVO), has published a new guideline for the secondary prevention of osteoporotic fractures. According to the guideline, women are screened using dual x-ray absorptiometry (DXA). Those with an absolute 10-year...
Persistent link: https://www.econbiz.de/10005590427
A disconnection exists between our understanding of osteoporosis diagnosis/treatment and our ability to provide optimal … the attitude that osteoporosis is a disease worthy of management), direction (focusing on the ultimate goal of … osteoporosis diagnosis and management, i.e. reduction in fracture), and flow (making it easy to do the right thing, i.e. taking the …
Persistent link: https://www.econbiz.de/10005590117
Background: The aging of the population is likely to increase the number of osteoporosis-related fractures, such as hip … interest. Objective: The aim of this study was to determine the cost effectiveness of preventive services for osteoporosis …
Persistent link: https://www.econbiz.de/10010614268
The economic burden associated with osteoporosis is considerable. As such, cost-effectiveness analyses are important … of treating post-menopausal osteoporosis with bisphosphonates and identify the key factors that influence the cost …-menopausal osteoporosis in the Swiss setting. Outcomes were compared with similar studies in Western European countries. Three cost …
Persistent link: https://www.econbiz.de/10010614280